Literature DB >> 19635998

Immunotherapy for prostate cancer: walk, don't run.

Charles G Drake.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19635998     DOI: 10.1200/JCO.2009.22.2299

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  19 in total

1.  Don't run before you can walk.

Authors:  Licia Rivoltini; Andrea Marrari; Chiara Castelli; Sergio Villa; Riccardo Valdagni
Journal:  Nat Rev Urol       Date:  2012-09-25       Impact factor: 14.432

2.  Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer.

Authors:  Alexander Kutikov; Peter Makhov; Konstantin Golovine; Daniel J Canter; Mohit Sirohi; Ryan Street; Jay Simhan; Robert G Uzzo; Vladimir M Kolenko
Journal:  Urology       Date:  2011-10       Impact factor: 2.649

Review 3.  Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.

Authors:  C Alberti
Journal:  G Chir       Date:  2017 Sep-Oct

Review 4.  Cancer immunotherapy: sipuleucel-T and beyond.

Authors:  Aimee E Hammerstrom; Diana H Cauley; Bradley J Atkinson; Padmanee Sharma
Journal:  Pharmacotherapy       Date:  2011-08       Impact factor: 4.705

5.  Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?

Authors:  Pawel Kalinski; Howard Edington; Herbert J Zeh; Hideho Okada; Lisa H Butterfield; John M Kirkwood; David L Bartlett
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

Review 6.  Targeting inhibitory pathways in cancer immunotherapy.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Curr Opin Immunol       Date:  2010-05-12       Impact factor: 7.486

Review 7.  Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.

Authors:  Pawel Kalinski; Hideho Okada
Journal:  Semin Immunol       Date:  2010-04-20       Impact factor: 11.130

8.  Oncolytic virus-initiated protective immunity against prostate cancer.

Authors:  Shashi A Gujar; D A Pan; Paola Marcato; Katy A Garant; Patrick W K Lee
Journal:  Mol Ther       Date:  2011-01-18       Impact factor: 11.454

Review 9.  Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.

Authors:  Ronnie H Fang; Ashley V Kroll; Liangfang Zhang
Journal:  Small       Date:  2015-09-02       Impact factor: 13.281

Review 10.  Proposed mechanisms of action for prostate cancer vaccines.

Authors:  Sean M Geary; Caitlin D Lemke; David M Lubaroff; Aliasger K Salem
Journal:  Nat Rev Urol       Date:  2013-02-12       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.